




Healthcare Industry News: MedShape
News Release - March 5, 2010
MedShape Solutions, Inc. Announces Commercialization of SBIR-funded Technology: Receives Purchasing Preference in Federally-funded Hospitals and Healthcare Facilities
ATLANTA, March 5, 2010 - (HSMN NewsFeed) - MedShape Solutions announced today that it is pursuing Phase III SBIR awards and has received preferred vendor status at Veterans Health Administration Hospitals and other Federally funded hospitals for its MORPHIX™ Shape Memory Suture Anchor. The MORPHIX device was developed with financial assistance through NIH/NIAMS Grants # 1R43AR056154-01, 2R44AR056154-02, 5R44AR056154-03. The MORPHIX Anchor is being highlighted and launched nationally at the American Academy of Orthopedic Surgeons meeting in New Orleans, March 10-13, 2010.“The development of the MORPHIX Suture Anchor with SBIR support was a textbook case of how a partnership in development should occur. The grant funding received was critical to the development success and eventual commercialization of this innovative technology,” stated Chris Fair, Chief Operations Officer of MedShape Solutions.
MedShape Solutions initial product is the MORPHIX Suture Anchor made from proprietary shape memory PEEK Altera. “We anticipate releasing additional technologies in the months ahead that were supported via SBIR Phase I & Phase II awards for their development. These technologies will also receive the same preferred supplier status within their product category”, stated Kurt Jacobus, PhD, President & CEO of MedShape Solutions.
MedShape Solutions is a privately held company focused on developing orthopedic devices from proprietary shape memory technology. You may find more information at www.MedShape.com.
If you are a government purchasing group and would like additional information, please contact Chris Fair, Chief Operating Officer of MedShape Solutions at (404) 249-9155 or send an email to gov@MedShape.com .
Source: MedShape Solutions
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.